TR199801367A3 - 5H- tiazol (3,2-a) pirimidin türevleri - Google Patents

5H- tiazol (3,2-a) pirimidin türevleri

Info

Publication number
TR199801367A3
TR199801367A3 TR1998/01367A TR9801367A TR199801367A3 TR 199801367 A3 TR199801367 A3 TR 199801367A3 TR 1998/01367 A TR1998/01367 A TR 1998/01367A TR 9801367 A TR9801367 A TR 9801367A TR 199801367 A3 TR199801367 A3 TR 199801367A3
Authority
TR
Turkey
Prior art keywords
thiazole
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
TR1998/01367A
Other languages
English (en)
Other versions
TR199801367A2 (tr
Inventor
Adam Geo
Kolczewski Sabine
Mutel Vincent
Wichmann Juergen
Johannes Woltering Thomas
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of TR199801367A2 publication Critical patent/TR199801367A2/tr
Publication of TR199801367A3 publication Critical patent/TR199801367A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TR1998/01367A 1997-07-18 1998-07-14 5H- tiazol (3,2-a) pirimidin türevleri TR199801367A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97112324 1997-07-18

Publications (2)

Publication Number Publication Date
TR199801367A2 TR199801367A2 (tr) 1999-02-22
TR199801367A3 true TR199801367A3 (tr) 1999-02-22

Family

ID=8227080

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01367A TR199801367A3 (tr) 1997-07-18 1998-07-14 5H- tiazol (3,2-a) pirimidin türevleri

Country Status (33)

Country Link
US (1) US5958931A (tr)
EP (1) EP0891978B1 (tr)
JP (1) JP3100573B2 (tr)
KR (1) KR100296837B1 (tr)
CN (1) CN1102596C (tr)
AR (1) AR016129A1 (tr)
AT (1) ATE214704T1 (tr)
AU (1) AU738207B2 (tr)
BR (1) BR9802482A (tr)
CA (1) CA2243234C (tr)
CO (1) CO5210884A1 (tr)
CZ (1) CZ288944B6 (tr)
DE (1) DE69804273T2 (tr)
DK (1) DK0891978T3 (tr)
ES (1) ES2172840T3 (tr)
HK (1) HK1018439A1 (tr)
HR (1) HRP980398B1 (tr)
HU (1) HUP9801587A3 (tr)
ID (1) ID21824A (tr)
IL (1) IL125358A (tr)
MA (1) MA26520A1 (tr)
NO (1) NO310512B1 (tr)
NZ (1) NZ330988A (tr)
PE (1) PE97499A1 (tr)
PL (1) PL190218B1 (tr)
PT (1) PT891978E (tr)
RU (1) RU2197493C2 (tr)
SI (1) SI0891978T1 (tr)
TR (1) TR199801367A3 (tr)
TW (1) TW523518B (tr)
UY (1) UY25095A1 (tr)
YU (1) YU29798A (tr)
ZA (1) ZA986250B (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
BR0206844A (pt) * 2001-01-31 2005-07-12 Synaptic Pharma Corp Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
WO2002102807A1 (fr) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Nouveaux derives d'isoxazolopyridone et leur utilisation
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
KR100847160B1 (ko) * 2004-06-21 2008-07-17 에프. 호프만-라 로슈 아게 피라졸로 피리미딘 유도체
CN100528876C (zh) * 2004-06-21 2009-08-19 弗·哈夫曼-拉罗切有限公司 吡唑并嘧啶衍生物
ES2365406T3 (es) 2005-02-11 2011-10-04 F. Hoffmann-La Roche Ag Derivados de pirazolo-pirimidina como antagonistas de mglur2.
EP1863818B1 (en) 2005-03-23 2010-03-10 F.Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
RS51660B (en) * 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`, 3`-DISUPSTITUATED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1`H- [1,4`] BIPYRIDINYL-2`-ONE
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
RU2512283C2 (ru) 2008-11-28 2014-04-10 Янссен Фармасьютикалз, Инк. Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ME01573B (me) 2009-05-12 2014-09-20 Addex Pharma Sa DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-***并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
JP6419800B2 (ja) 2013-10-11 2018-11-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎｍｄａ受容体活性の調節因子としてのチアゾロピリミジノン
KR102502485B1 (ko) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
MX2019011785A (es) * 2017-03-31 2019-11-18 Basf Se Proceso para preparar compuestos de 2,3-dihidrotiazolo[3,2-a]pirim idin-4-io quirales.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660418A (en) * 1970-03-16 1972-05-02 Sandoz Ag Certain 2 3 5 6-tetrahydroimidazo(2 1-b)thiazoles
EP0524055A1 (fr) * 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
WO1998006724A1 (fr) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique

Also Published As

Publication number Publication date
JP3100573B2 (ja) 2000-10-16
IL125358A0 (en) 1999-03-12
RU2197493C2 (ru) 2003-01-27
IL125358A (en) 2002-09-12
NO310512B1 (no) 2001-07-16
ID21824A (id) 1999-07-29
YU29798A (sh) 2001-12-26
CA2243234C (en) 2007-09-18
ZA986250B (en) 1999-01-22
CZ223998A3 (cs) 1999-02-17
KR100296837B1 (ko) 2001-10-26
DK0891978T3 (da) 2002-07-01
TR199801367A2 (tr) 1999-02-22
PL327532A1 (en) 1999-02-01
KR19990013919A (ko) 1999-02-25
US5958931A (en) 1999-09-28
EP0891978B1 (en) 2002-03-20
TW523518B (en) 2003-03-11
HRP980398B1 (en) 2002-06-30
DE69804273T2 (de) 2002-10-31
HK1018439A1 (en) 1999-12-24
NO983244L (no) 1999-01-19
DE69804273D1 (de) 2002-04-25
HUP9801587A2 (hu) 1999-11-29
EP0891978A3 (en) 1999-02-03
NO983244D0 (no) 1998-07-14
PL190218B1 (pl) 2005-11-30
CN1206010A (zh) 1999-01-27
CA2243234A1 (en) 1999-01-18
MA26520A1 (fr) 2004-12-20
AU7730298A (en) 1999-01-28
ATE214704T1 (de) 2002-04-15
EP0891978A2 (en) 1999-01-20
PE97499A1 (es) 1999-10-12
UY25095A1 (es) 2001-01-31
HRP980398A2 (en) 1999-04-30
PT891978E (pt) 2002-07-31
HU9801587D0 (en) 1998-09-28
AR016129A1 (es) 2001-06-20
AU738207B2 (en) 2001-09-13
CO5210884A1 (es) 2002-10-30
CN1102596C (zh) 2003-03-05
HUP9801587A3 (en) 2001-09-28
CZ288944B6 (cs) 2001-10-17
JPH1171380A (ja) 1999-03-16
BR9802482A (pt) 2000-03-14
SI0891978T1 (en) 2002-06-30
NZ330988A (en) 1999-03-29
ES2172840T3 (es) 2002-10-01

Similar Documents

Publication Publication Date Title
ATE214704T1 (de) 5h-thiazolo(3,2-a)pyrimidinderivate
ATE284404T1 (de) Pyrazolo(4,3-d)pyrimidinderivate
NO20006454D0 (no) Pyrrolo(2,3-d)pyrimidinforbindelser
NO20006453D0 (no) Pyrrolo(2,3-d)pyrimidinforbindelser
ATE261970T1 (de) Triazolo(4,5-d)pyrimidin-derivate
NO20022738D0 (no) Pyrrolo(2,3-d)pyrimidinforbindelser
ATE256123T1 (de) Pyrimidonderivate
ID19773A (id) Turunan-turunan 1,3,8-triaza-spiro (4,5) dekan-4-ona tersubtitusi-8
NO993658D0 (no) Sulfonylurea-derivater
NL300150I1 (nl) 4"-Gesubstitueerde 9-deoxo-9A-AZA-9A-homoërythromycine-A-derivaten.
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
DE69511086T2 (de) Pyrimidinderivate
TR199802520A3 (tr) 1,3,8-Triaza-spiro(4,5) dekan -4-on türevleri.
TR199800988A3 (tr) 5' Deoksi-Sitidin türevleri.
DE69716901D1 (de) 2,4-diaminopyrimidin-derivate
ATE204279T1 (de) Diaza-spiro(3,5)nonan-derivate
NO995033D0 (no) 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
NO995035D0 (no) 5,6,7-trisubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
PT1010699E (pt) Derivados de 3-oxadiazolil-1,6-naftiridina-2(h)-ona substituido em 5
EP0954316A4 (en) PYRIMIDINE DERIVATIVES